The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1467
April 27, 2015
View Complete Issue         Table of Contents 2019 
Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (online only)
April 27, 2015 (Issue: 1467)
The FDA has approved belinostat (Beleodaq – Spectrum), an IV histone deacetylase (HDAC) inhibitor, for treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is the third IV drug approved by the FDA for PTCL....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (online only)
Article code: 1467g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.